Top

Optie A:

Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
Optie B:

Deel de link per e-mail
Link delen

vorige artikel Test–retest reliability of HeartQoL and its com...

volgende artikel Baseline overall health-related quality of life...

Tip

Swipe om te navigeren naar een ander artikel

15-08-2015 | Commentary | Uitgave 2/2016

International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies

Tijdschrift:: Quality of Life Research > Uitgave 2/2016

Auteurs:: Derek Kyte, Bryce B. Reeve, Fabio Efficace, Kirstie Haywood, Rebecca Mercieca-Bebber, Madeleine T. King, Josephine M. Norquist, William R. Lenderking, Claire Snyder, Lena Ring, Galina Velikova, Melanie Calvert

» Toegang tot de volledige tekst krijgen

Belangrijke opmerkingen

Disclaimers: This paper was reviewed and endorsed by the International Society for Quality of Life Research (ISOQOL) Board of Directors as an ISOQOL publication and does not reflect an endorsement of the ISOQOL membership. The opinions or assertions in this article are the views of the authors and are not to be construed as official or as reflecting the views of the Medical Products Agency, Sweden.

Abstract

In 2014, the European Medicines Agency (EMA) released for comment a draft reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. A twelve-member International Society for Quality of Life Research (ISOQOL) taskforce was convened to coordinate the ISOQOL response. Twenty-one ISOQOL members provided detailed comments and suggestions on the paper: 81 % from academia and 19 % from industry. Taskforce members consolidated and further refined these comments and shared the recommendations with the wider ISOQOL membership. A final response was submitted to the EMA in November 2014. The impending publication of the EMA reflection paper presents a valuable opportunity for ISOQOL to comment on the current direction of EMA PRO guidance and strategy. The EMA paper, although focused on cancer, could serve as a model for using PROs in other conditions, as it provides a useful update surrounding some of the design issues common to all trial research including PRO endpoints. However, we believe there are a number of additional areas in need of greater consideration. The purpose of this commentary is therefore to highlight the strengths of this timely and potentially useful document, but also to outline areas that may warrant further discussion.

Log in om toegang te krijgen

Hier inloggen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Podotherapeut Totaal

Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.

Meer informatie

EMA. (2014). Reflection Paper on the use of patient reported outcome (PRO) measures in oncology studies [Draft]. European Medicines Agency, Oncology Working Party; Doc. Ref. EMA/CHMP/292464/2014.

EMA. (2005). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. European Medicines Agency, Committee for medicinal products for human use (CHMP); Doc. Ref. EMEA/CHMP/EWP/139391/2004.

ISOQOL. (2015). International Society for Quality of Life Research. http://www.isoqol.org/research/isoqol-publications. Accessed July 2015.

Kyte, D., Ives, J., Draper, H., Keeley, T., & Calvert, M. (2013). Inconsistencies in quality of life data collection in clinical trials: A potential source of bias? Interviews with research nurses and trialists. PLoS One, 8(10), e76625. PubMedCentralCrossRefPubMed

Kyte, D. G., Draper, H., Ives, J., Liles, C., Gheorghe, A., & Calvert, M. (2013). Patient reported outcomes (PROs) in clinical trials: is ‘in-trial’ guidance lacking? A systematic review. PLoS One, 8(4), e60684. PubMedCentralCrossRefPubMed

Basch, E. M., Abernethy, A., Mullins, C. D., Tiglao, M. R., & Tunis, S. R. (2011). Development of a guidance for including patient-reported outcomes (PROS) in post-approval clinical trials of oncology drugs for comparative effectiveness research (CER). Value in Health, 14(3), A10. CrossRef

FDA. (2009). Guidance for industry: Patient- reported outcome measures: Use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf

Reeve, B. B., Mitchell, S. A., Dueck, A. C., Basch, E., Cella, D., & Reilly, C. M. et al. (2014). Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. Journal of the National Cancer Institute, 106(7), dju129.

Brundage, M., Bass, B., Davidson, J., Queenan, J., Bezjak, A., Ringash, J., et al. (2011). Patterns of reporting health-related quality of life outcomes in randomized clinical trials: Implications for clinicians and quality of life researchers. Quality of Life Research, 20, 653–664. CrossRefPubMed

10.

Calvert, M., Blazeby, J., Altman, D. G., Revicki, D., Moher, D., & Brundage, M. (2013). Reporting of patient reported outcomes in randomised trials: The CONSORT PRO extension. JAMA, 309(8), 814–822. CrossRefPubMed

11.

International Society for Quality of Life Research. Best practices for PROs in randomized clinical trials taskforce. http://www.isoqol.org/about-isoqol/committees/best-practices-for-pros-in-randomized-clinical-trials. Accessed February 17, 2015.

12.

Taphoorn, M. J., Stupp, R., Coens, C., Osoba, D., Kortmann, R., van den Bent, M. J., et al. (2005). Health-related quality of life in patients with glioblastoma: A randomised controlled trial. The lancet Oncology, 6(12), 937–944. CrossRefPubMed

13.

Marin, D., Bazeos, A., Mahon, F.-X., Eliasson, L., Milojkovic, D., Bua, M., et al. (2010). Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. Journal of Clinical Oncology, 28(14), 2381–2388. CrossRefPubMed

14.

Brett, J., Staniszewska, S., Mockford, C., Herron‐Marx, S., Hughes, J., & Tysall, C. et al. (2014). Mapping the impact of patient and public involvement on health and social care research: A systematic review. Health Expectations, 17(5), 637–650. CrossRef

15.

Gradinger, F., Britten, N., Wyatt, K., Froggatt, K., Gibson, A., & Jacoby, A. et al. (2013). Values associated with public involvement in health and social care research: A narrative review. Health Expectations. doi: 10.1111/hex.12158.

16.

de Wit, M. P., Abma, T. A., Koelewijn-van Loon, M. S., Collins, S., & Kirwan, J. (2014). What has been the effect on trial outcome assessments of a decade of patient participation in OMERACT? The Journal of Rheumatology, 41(1), 177–184. CrossRefPubMed

17.

Staniszewska, S., Haywood, K. L., Brett, J., & Tutton, L. (2012). Patient and public involvement in patient-reported outcome measures. The Patient-Patient-Centered Outcomes Research, 5(2), 79–87. CrossRefPubMed

18.

Kirwan, J. R., Minnock, P., Adebajo, A., Bresnihan, B., Choy, E., De Wit, M., et al. (2007). Patient perspective: Fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. The Journal of Rheumatology, 34(5), 1174–1177. PubMed

19.

Nicklin, J., Cramp, F., Kirwan, J., Urban, M., & Hewlett, S. (2010). Collaboration with patients in the design of patient-reported outcome measures: Capturing the experience of fatigue in rheumatoid arthritis. Arthritis Care & Research, 62(11), 1552–1558. CrossRef

Titel: International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies
Auteurs:: Derek Kyte
Bryce B. Reeve
Fabio Efficace
Kirstie Haywood
Rebecca Mercieca-Bebber
Madeleine T. King
Josephine M. Norquist
William R. Lenderking
Claire Snyder
Lena Ring
Galina Velikova
Melanie Calvert
Publicatiedatum: 15-08-2015
DOI: https://doi.org/10.1007/s11136-015-1099-z
Uitgeverij: Springer International Publishing
Tijdschrift: Quality of Life Research An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation - An Official Journal of the International Society of Quality of Life Research
Uitgave 2/2016
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Tip

Swipe om te navigeren naar een ander artikel

Abstract

Log in om toegang te krijgen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Podotherapeut Totaal

Andere artikelen Uitgave 2/2016

Associations between adult attachment and: oral health-related quality of life, oral health behaviour, and self-rated oral health

Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement

Test–retest reliability of HeartQoL and its comparability to the MacNew heart disease health-related quality of life questionnaire

The definition and role of quality of life in Germany’s early assessment of drug benefit: a qualitative approach

Correcting bias in self-rated quality of life: an application of anchoring vignettes and ordinal regression models to better understand QoL differences across commuting modes

Gender, race, BMI, and social support in relation to the health-related quality of life of cancer survivors: a report from the American Cancer Society’s Study of Cancer Survivors II (SCS-II)